Bioelectronics Corp (BIEL)

[jebco]

Investor Update is Out:

BioElectronics Investor Update


BioElectronics Investor Update – Thursday, June 21, 2012




INDIA

Juno Pharmaceuticals – Medical Division, is an interesting company formed in 2011 by a Canadian venture fund and developed and funded by experienced pharmaceutical executives. Juno is committed to bringing reliable, long-lasting and quality products from the world over to cater to medical specialists, institutions, distributors and associates with particular focus on opportunities in Asia, Africa and Asia Pacific.

Juno Pharmaceuticals has launched an Ecommerce website at http://www.actipatch.in, which is now accepting orders for BIEL’s ActiPatch® pain relief devices. Juno is announcing an aggressive marketing campaign designed to reach the growing middle class in India. Juno has reported that medical professionals who have used the product report positive results. Visit Juno on Facebook: http://www.facebook.com/junopharm or follow them on Twitter: https://twitter.com/junopharminc.

Senator Mikulski

The management and Board of Directors deeply appreciate the assistance and efforts of Senator Barbara Mikulski and her staff. Senator Mikulski forwarded us the FDA’s response to her inquiries on BioElectronics Corporation’s behalf. You may review both letters here: http://bielcorp.com/wp-content/uploads/2012/06/Barbara-Mikulski-Letter-to-BIEL-6-14-12.pdf

FDA

Allay

We were pleased with the Friday, June 8, meeting with the FDA. At the meeting we addressed the application of the technology to support our menstrual pain medical claim for Allay.

Dr. Kenneth McLeod, our consulting biophysics expert, made the technical presentation. Dr. McLeod received his PhD from MIT in electrical engineering, with a dissertation focused on electrophysiological properties of living tissue, and has worked in the field of bioelectromagnetics for more than 30 years. He is currently Director of the Clinical Science and Engineering Research Center at Binghamton University where the research is largely focused on functional disorders (such as chronic pain) and interventions to address these disorders. BioElectronics’ Chairman, Dr. Richard Staelin, is a mathematician and statistician, and was in attendance to support the clinical data analysis. Andrew Whelan was also in attendance at the meeting.

RecoveryRx

We have a teleconference meeting with the FDA in July regarding our RecoveryRX™ post-surgical product.

ActiPatch

Our request for over-the-counter classification of the ActiPatch products is going through final review and concurrence processes.